MiNK Therapeutics, Inc. (INKT) stock
INKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$9.29−0.06 (-0.70%)
Close on Nov 17, 2026Market cap $47.38MP/E –Yield –
MiNK Therapeutics cash
Cash and short-term investments held at the end of each period.
MiNK Therapeutics's cash was $8.81M at Jun 30, 2026. For fiscal 2025 it was $13.36M, up 191.9% from the year before. The highest annual figure on record is $38.89M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.36M | +191.9% |
| FY2024 | Dec 31, 2024 | $4.58M | +35.9% |
| FY2023 | Dec 31, 2023 | $3.37M | -82.9% |
| FY2022 | Dec 31, 2022 | $19.64M | -49.5% |
| FY2021 | Dec 31, 2021 | $38.89M | +1345.1% |
| FY2020 | Dec 31, 2020 | $2.69M | +799.9% |
| FY2019 | Dec 31, 2019 | $299.04K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $8.81M | +423.6% |
| Q1 FY2026 | Mar 31, 2026 | $9.53M | +194.5% |
| Q4 FY2025 | Dec 31, 2025 | $13.36M | +191.9% |
| Q3 FY2025 | Sep 30, 2025 | $9.50M | +50.1% |
| Q2 FY2025 | Jun 30, 2025 | $1.68M | -81.9% |
| Q1 FY2025 | Mar 31, 2025 | $3.23M | -44.4% |
| Q4 FY2024 | Dec 31, 2024 | $4.58M | +35.9% |
| Q3 FY2024 | Sep 30, 2024 | $6.33M | -1.1% |
| Q2 FY2024 | Jun 30, 2024 | $9.31M | -12.3% |
| Q1 FY2024 | Mar 31, 2024 | $5.82M | -60.9% |
| Q4 FY2023 | Dec 31, 2023 | $3.37M | -82.9% |
| Q3 FY2023 | Sep 30, 2023 | $6.40M | -73.5% |
| Q2 FY2023 | Jun 30, 2023 | $10.62M | -64.4% |
| Q1 FY2023 | Mar 31, 2023 | $14.89M | -57.1% |
| Q4 FY2022 | Dec 31, 2022 | $19.64M | -49.5% |
| Q3 FY2022 | Sep 30, 2022 | $24.16M | +2848.1% |
| Q2 FY2022 | Jun 30, 2022 | $29.85M | +1699.8% |
| Q1 FY2022 | Mar 31, 2022 | $34.69M | +4181.1% |
| Q4 FY2021 | Dec 31, 2021 | $38.89M | +1345.1% |
| Q3 FY2021 | Sep 30, 2021 | $819.45K | -36.3% |
| Q2 FY2021 | Jun 30, 2021 | $1.66M | +454.6% |
| Q1 FY2021 | Mar 31, 2021 | $810.27K | – |
| Q4 FY2020 | Dec 31, 2020 | $2.69M | – |
| Q3 FY2020 | Sep 30, 2020 | $1.29M | – |
| Q4 FY2019 | Dec 31, 2019 | $299.04K | – |
See a number that looks wrong?